AstraZeneca PLC
1423.50
13-November-24 10:24:56
15 minutes delayed
Stocks
+15.50
+1.10%
Today's range
1413.50 - 1446.00
ISIN
N/A
Source
Cboe
-
NetDania - New 12 months High: AstraZeneca PLC
16 Aug 2024 02:17:04 By NetDania Notify
-
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
15 Aug 2024 06:38:12 By NASDAQ Stocks
-
NetDania - New 12 months High: AstraZeneca PLC
15 Aug 2024 02:15:16 By NetDania Notify
-
NetDania - New 12 months High: AstraZeneca PLC
13 Aug 2024 02:19:30 By NetDania Notify
-
Ex-Dividend Reminder: Cencora, AstraZeneca and Wells Fargo
07 Aug 2024 09:27:01 By NASDAQ Stocks
-
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
04 Aug 2024 09:42:17 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
29 Jul 2024 07:07:19 By NetDania Notify
-
AstraZeneca: Calquence Combo Enhances PFS In First-Line CLL In Phase III Trial
29 Jul 2024 02:38:02 By NASDAQ US Markets
-
AstraZeneca Reports ODAC's Review Of Imfinzi - Quick Facts
26 Jul 2024 02:05:05 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
25 Jul 2024 02:15:03 By NetDania Notify
-
AstraZeneca Q2 Profit Rises, Lifts FY24 Outlook
25 Jul 2024 01:51:34 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
23 Jul 2024 05:15:26 By NetDania Notify
-
NetDania - New 12 months High: AstraZeneca PLC
22 Jul 2024 07:17:57 By NetDania Notify
-
Interesting AZN Put And Call Options For August 23rd
03 Jul 2024 12:16:51 By NASDAQ US Markets
-
AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer
01 Jul 2024 02:09:21 By NASDAQ US Markets
-
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
28 Jun 2024 09:33:02 By NASDAQ Stocks
-
AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer
25 Jun 2024 02:08:02 By NASDAQ US Markets
-
AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer
18 Jun 2024 02:15:21 By NASDAQ US Markets
-
AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial
16 Jun 2024 11:33:03 By NASDAQ US Markets
-
FDA Approves AstraZeneca's Farxiga For Pediatric Use In Type-2 Diabetes
12 Jun 2024 20:53:19 By NASDAQ US Markets